Editorial Board
Publication date: December 2010Source: Digestive and Liver Disease Supplements, Volume 4, Issue 1Author(s): (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

The Italian clinical experience with adalimumab in Crohn's disease: Eleven clinical cases
Publication date: December 2010Source: Digestive and Liver Disease Supplements, Volume 4, Issue 1Author(s): Maria Laura Annunziata, Fabrizio Bossa, Rosamaria Bozzi, Flavio Caprioli, Andrea Cassinotti, Giuseppe Costantino, Gionata Fiorino, Sara Onali, Mariabeatrice Principi, Sara Renna, Rosy Tambasco (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Spondyloarthropathy associated with Crohn's disease treated with adalimumab
Publication date: December 2010Source: Digestive and Liver Disease Supplements, Volume 4, Issue 1Author(s): Maria Laura Annunziata, Michele Cicala (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Long-term remission with adalimumab in steroid-dependent Crohn's disease patients with multiple drug intolerances
Publication date: December 2010Source: Digestive and Liver Disease Supplements, Volume 4, Issue 1Author(s): Fabrizio Bossa, Giuseppe Biscaglia, Antonio Merla, Fulvia Terracciano (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Adalimumab and endoscopic dilatation in the treatment of inflammatory strictures due to Crohn's disease: A case report of a treatment-naïve patient
Publication date: December 2010Source: Digestive and Liver Disease Supplements, Volume 4, Issue 1Author(s): Rosamaria Bozzi, Pietro Schettino, Angelo Pezzullo, Domenico Cattaneo (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Adalimumab is safe and effective in re-inducing clinical remission after post-surgical relapse of Crohn's disease: A case report
We present the case of a 36-year-old patient with ileo-colonic stricturing Crohn's disease that recurred after surgery, did not respond to maximal medical therapy and was only partially responsive to treatment with adalimumab administered subcutaneously. The patient underwent surgery following an episode of intestinal obstruction, revealing chronic, adhesive peritonitis, with the intestinal loops fixed strongly together, and a fibrotic stricture of the pre-anastomotic ileum. The numerous adhesions were carefully separated and the stenotic tract of ileum was resected. Following the resection the patient had an early clinica...
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Is mucosal healing a predictor of decreased risk of Crohn's disease relapse after withdrawal of 1-year, successful adalimumab?
Publication date: December 2010Source: Digestive and Liver Disease Supplements, Volume 4, Issue 1Author(s): Andrea Cassinotti, Maria Fichera, Sandro Ardizzone, Gabriele Bianchi Porro (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Prevention of post-surgical recurrence with adalimumab in a patient with complicated Crohn's disease
Publication date: December 2010Source: Digestive and Liver Disease Supplements, Volume 4, Issue 1Author(s): Giuseppe Costantino, Giuseppe Navarra, Luigi Familiari, Walter Fries (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Adalimumab is effective in achieving clinical and endoscopic long-term deep remission: A case report
We report the case of a 61-year-old woman with aggressive and complicated steroid-dependant Crohn's disease in whom clinical and endoscopic long-term deep remission was achieved for up to 3 years, without any need for steroids, hospitalization or surgery. (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Steroid-free remission and closure of recto-vaginal fistula using adalimumab in a Crohn's disease patient naïve to anti-tumour necrosis factor alpha antibodies
Publication date: December 2010Source: Digestive and Liver Disease Supplements, Volume 4, Issue 1Author(s): Sara Onali, Francesca Zorzi, Emma Calabrese, Livia Biancone (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Adalimumab and perianal Crohn's disease: Case report
Publication date: December 2010Source: Digestive and Liver Disease Supplements, Volume 4, Issue 1Author(s): Mariabeatrice Principi, Nicola De Tullio, Alfredo di Leo (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Combined treatment with adalimumab and surgery in a patient with steroid-dependent Crohn's disease complicated by perianal disease
Publication date: December 2010Source: Digestive and Liver Disease Supplements, Volume 4, Issue 1Author(s): Sara Renna, Ambrogio Orlando, Gaspare Solina, Mario Cottone (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Adalimumab in a patient with steroid-dependent Crohn's disease
We present the case of 51-year-old man with stricturing Crohn's disease of the jejunum and ileum who underwent jejunal resection and creation of a latero-lateral anastomosis. The patient had a history of steroid-dependent disease and was inappropriately treated with azathioprine, complicated by vertebral collapse. Adalimumab administered subcutaneously was used because of the persistence of active disease. (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Editorial Board
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

2nd Liver Transplantation, HBV and HCV Interdisciplinary Conference
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): Rafael Esteban, Franco Filipponi (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Current challenges and future trends in liver transplantation
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): Manuel L. Rodríguez-Perálvarez, Jose Luis Montero, Manuel De la Mata GarcíaAbstractIn Liver Transplantation (LT) units the clinicians routinely deal with complex decision making situations that cannot always be solved with the available scientific evidence. They include selection of the best candidates for LT, minimizing mortality and drop-out rates within the waiting list (WL) and rationalizing donor–recipient matching. These topics constitute some of the current challenges in LT and they ...
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Liver transplantation: is it a sustainable practice?
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): Franco FilipponiAbstractDespite its widespread diffusion, liver transplantation (LT) still remains one of the most resource consuming surgical procedures. In times of economic constraints, the entire medical community is discussing the strategies necessary to allow a sustainable development of LT. Sustainability is the capacity to endure and, in ecology, the word describes how biological systems remain diverse and productive over time. In clinical practice, sustainability is the potential for long-term maintenance of...
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Management of hepatitis B virus infection in the pre-transplant setting
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): Martín Prieto, María García-ElizAbstractLiver transplantation remains the ultimate cure for patients with hepatitis B virus-related end-stage liver disease. Clinical Practice Guidelines currently recommend that patients with decompensated HBV cirrhosis should be treated without delay with nucleos(t)ide analogues regardless of the patient's serum ALT, HBV DNA level, and HBeAg status. The main goal of pre-transplantation antiviral therapy is to achieve a rapid and prolonged suppression of viral rep...
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Optimization of hepatitis B virus prophylaxis after liver transplantation
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): Paolo De SimoneAbstractA combination of hepatitis B immunoglobulins (HBIg) and nucleos(t)ide analogues (NA) is currently recommended for HBV prophylaxis after liver transplantation (LT), but the optimal regimen is still controversial. Several issues concerning use of HBIg after LT still await definitive clarification, such as dosage (high vs. low); timing (ab initio vs. delayed); schedule (on demand vs. fixed-dose); route of administration (intravenous vs. intramuscular vs. subcutaneous), and duration (short-term vs....
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Management of HBV resistance in the post-transplant setting
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): Alfredo MarzanoAbstractIn western countries, about 10–25% of patients undergoing liver transplantation (LT) are HBsAg carriers. In Asia, HBV-related liver disease is the leading indication to LT. After surgery hepatitis B can develop in patients transplanted for HBV-related disease or in HBsAg-negative recipients of anti-HBc positive grafts. In the last years prophylaxis with HBIG and/or antivirals has been proposed in both conditions with excellent results. However, lack of efficacy of prophylaxis is frequentl...
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Non-invasive diagnosis of liver fibrosis in the transplant setting
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): Gonzalo Crespo, Zoe MariñoAbstractRecurrent hepatitis C after liver transplantation is a rapidly evolving condition in which fibrosis deposition is accelerated, with 30% of patients developing graft cirrhosis within the first 5 years after transplantation. Antiviral therapy after transplantation achieves sustained virological response (SVR) in approximately 30% of patients, and a milder fibrosis stage at treatment seems to increase the probabilities of response to treatment. Importantly, SVR to antiviral thera...
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Treatment of hepatitis C in the post-transplant setting
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): Marina BerenguerAbstractCirrhosis with/without hepatocellular carcinoma is the primary indication for liver transplantation (LT) in many countries. Hepatitis C virus (HCV) reinfection occurs universally resulting in HCV-graft disease with progression to cirrhosis in about one third of cases after 5 years. Graft failure secondary to recurrent HCV is now the most frequent cause of death, graft failure and need for retransplantation in these patients, with a cumulative risk of allograft failure due to recurrent disease ...
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Facing HCV recurrence after liver transplantation: antiviral therapy response and clinical outcome
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): Maria Rendina, Stefano Fagiuoli, Patrizia Burra, Nicola Maurizio Castellaneta, Marianna Zappimbulso, Antonio Castellaneta, Roberto Bringiotti, Salvatore Fiabio Rizzi, Annamaria Squicciarino, Luigi Lupo, Alfredo Di LeoAbstractEnd-stage liver disease related to HCV infection is the most common indication for liver transplantation both in Europe and in USA (http://www.UNOS.org; http://www.ELTR.org). The results of liver transplantation for this indication are negatively affected by the high rate of viral recurrence whic...
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Editorial Board
Publication date: December 2010Source: Digestive and Liver Disease Supplements, Volume 4, Issue 1Author(s): (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

The Italian clinical experience with adalimumab in Crohn's disease: Eleven clinical cases
Publication date: December 2010Source: Digestive and Liver Disease Supplements, Volume 4, Issue 1Author(s): Maria Laura Annunziata, Fabrizio Bossa, Rosamaria Bozzi, Flavio Caprioli, Andrea Cassinotti, Giuseppe Costantino, Gionata Fiorino, Sara Onali, Mariabeatrice Principi, Sara Renna, Rosy Tambasco (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

Spondyloarthropathy associated with Crohn's disease treated with adalimumab
Publication date: December 2010Source: Digestive and Liver Disease Supplements, Volume 4, Issue 1Author(s): Maria Laura Annunziata, Michele Cicala (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

Long-term remission with adalimumab in steroid-dependent Crohn's disease patients with multiple drug intolerances
Publication date: December 2010Source: Digestive and Liver Disease Supplements, Volume 4, Issue 1Author(s): Fabrizio Bossa, Giuseppe Biscaglia, Antonio Merla, Fulvia Terracciano (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

Adalimumab and endoscopic dilatation in the treatment of inflammatory strictures due to Crohn's disease: A case report of a treatment-naïve patient
Publication date: December 2010Source: Digestive and Liver Disease Supplements, Volume 4, Issue 1Author(s): Rosamaria Bozzi, Pietro Schettino, Angelo Pezzullo, Domenico Cattaneo (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

Adalimumab is safe and effective in re-inducing clinical remission after post-surgical relapse of Crohn's disease: A case report
We present the case of a 36-year-old patient with ileo-colonic stricturing Crohn's disease that recurred after surgery, did not respond to maximal medical therapy and was only partially responsive to treatment with adalimumab administered subcutaneously. The patient underwent surgery following an episode of intestinal obstruction, revealing chronic, adhesive peritonitis, with the intestinal loops fixed strongly together, and a fibrotic stricture of the pre-anastomotic ileum. The numerous adhesions were carefully separated and the stenotic tract of ileum was resected. Following the resection the patient had an early clinica...
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

Is mucosal healing a predictor of decreased risk of Crohn's disease relapse after withdrawal of 1-year, successful adalimumab?
Publication date: December 2010Source: Digestive and Liver Disease Supplements, Volume 4, Issue 1Author(s): Andrea Cassinotti, Maria Fichera, Sandro Ardizzone, Gabriele Bianchi Porro (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

Prevention of post-surgical recurrence with adalimumab in a patient with complicated Crohn's disease
Publication date: December 2010Source: Digestive and Liver Disease Supplements, Volume 4, Issue 1Author(s): Giuseppe Costantino, Giuseppe Navarra, Luigi Familiari, Walter Fries (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

Adalimumab is effective in achieving clinical and endoscopic long-term deep remission: A case report
We report the case of a 61-year-old woman with aggressive and complicated steroid-dependant Crohn's disease in whom clinical and endoscopic long-term deep remission was achieved for up to 3 years, without any need for steroids, hospitalization or surgery. (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

Steroid-free remission and closure of recto-vaginal fistula using adalimumab in a Crohn's disease patient naïve to anti-tumour necrosis factor alpha antibodies
Publication date: December 2010Source: Digestive and Liver Disease Supplements, Volume 4, Issue 1Author(s): Sara Onali, Francesca Zorzi, Emma Calabrese, Livia Biancone (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

Adalimumab and perianal Crohn's disease: Case report
Publication date: December 2010Source: Digestive and Liver Disease Supplements, Volume 4, Issue 1Author(s): Mariabeatrice Principi, Nicola De Tullio, Alfredo di Leo (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

Combined treatment with adalimumab and surgery in a patient with steroid-dependent Crohn's disease complicated by perianal disease
Publication date: December 2010Source: Digestive and Liver Disease Supplements, Volume 4, Issue 1Author(s): Sara Renna, Ambrogio Orlando, Gaspare Solina, Mario Cottone (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

Adalimumab in a patient with steroid-dependent Crohn's disease
We present the case of 51-year-old man with stricturing Crohn's disease of the jejunum and ileum who underwent jejunal resection and creation of a latero-lateral anastomosis. The patient had a history of steroid-dependent disease and was inappropriately treated with azathioprine, complicated by vertebral collapse. Adalimumab administered subcutaneously was used because of the persistence of active disease. (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

Editorial Board
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

2nd Liver Transplantation, HBV and HCV Interdisciplinary Conference
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): Rafael Esteban, Franco Filipponi (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

Current challenges and future trends in liver transplantation
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): Manuel L. Rodríguez-Perálvarez, Jose Luis Montero, Manuel De la Mata GarcíaAbstractIn Liver Transplantation (LT) units the clinicians routinely deal with complex decision making situations that cannot always be solved with the available scientific evidence. They include selection of the best candidates for LT, minimizing mortality and drop-out rates within the waiting list (WL) and rationalizing donor–recipient matching. These topics constitute some of the current challenges in LT and they ...
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

Liver transplantation: is it a sustainable practice?
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): Franco FilipponiAbstractDespite its widespread diffusion, liver transplantation (LT) still remains one of the most resource consuming surgical procedures. In times of economic constraints, the entire medical community is discussing the strategies necessary to allow a sustainable development of LT. Sustainability is the capacity to endure and, in ecology, the word describes how biological systems remain diverse and productive over time. In clinical practice, sustainability is the potential for long-term maintenance of...
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

Management of hepatitis B virus infection in the pre-transplant setting
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): Martín Prieto, María García-ElizAbstractLiver transplantation remains the ultimate cure for patients with hepatitis B virus-related end-stage liver disease. Clinical Practice Guidelines currently recommend that patients with decompensated HBV cirrhosis should be treated without delay with nucleos(t)ide analogues regardless of the patient's serum ALT, HBV DNA level, and HBeAg status. The main goal of pre-transplantation antiviral therapy is to achieve a rapid and prolonged suppression of viral rep...
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

Optimization of hepatitis B virus prophylaxis after liver transplantation
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): Paolo De SimoneAbstractA combination of hepatitis B immunoglobulins (HBIg) and nucleos(t)ide analogues (NA) is currently recommended for HBV prophylaxis after liver transplantation (LT), but the optimal regimen is still controversial. Several issues concerning use of HBIg after LT still await definitive clarification, such as dosage (high vs. low); timing (ab initio vs. delayed); schedule (on demand vs. fixed-dose); route of administration (intravenous vs. intramuscular vs. subcutaneous), and duration (short-term vs....
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

Management of HBV resistance in the post-transplant setting
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): Alfredo MarzanoAbstractIn western countries, about 10–25% of patients undergoing liver transplantation (LT) are HBsAg carriers. In Asia, HBV-related liver disease is the leading indication to LT. After surgery hepatitis B can develop in patients transplanted for HBV-related disease or in HBsAg-negative recipients of anti-HBc positive grafts. In the last years prophylaxis with HBIG and/or antivirals has been proposed in both conditions with excellent results. However, lack of efficacy of prophylaxis is frequentl...
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

Non-invasive diagnosis of liver fibrosis in the transplant setting
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): Gonzalo Crespo, Zoe MariñoAbstractRecurrent hepatitis C after liver transplantation is a rapidly evolving condition in which fibrosis deposition is accelerated, with 30% of patients developing graft cirrhosis within the first 5 years after transplantation. Antiviral therapy after transplantation achieves sustained virological response (SVR) in approximately 30% of patients, and a milder fibrosis stage at treatment seems to increase the probabilities of response to treatment. Importantly, SVR to antiviral thera...
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

Treatment of hepatitis C in the post-transplant setting
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): Marina BerenguerAbstractCirrhosis with/without hepatocellular carcinoma is the primary indication for liver transplantation (LT) in many countries. Hepatitis C virus (HCV) reinfection occurs universally resulting in HCV-graft disease with progression to cirrhosis in about one third of cases after 5 years. Graft failure secondary to recurrent HCV is now the most frequent cause of death, graft failure and need for retransplantation in these patients, with a cumulative risk of allograft failure due to recurrent disease ...
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

Facing HCV recurrence after liver transplantation: antiviral therapy response and clinical outcome
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): Maria Rendina, Stefano Fagiuoli, Patrizia Burra, Nicola Maurizio Castellaneta, Marianna Zappimbulso, Antonio Castellaneta, Roberto Bringiotti, Salvatore Fiabio Rizzi, Annamaria Squicciarino, Luigi Lupo, Alfredo Di LeoAbstractEnd-stage liver disease related to HCV infection is the most common indication for liver transplantation both in Europe and in USA (http://www.UNOS.org; http://www.ELTR.org). The results of liver transplantation for this indication are negatively affected by the high rate of viral recurrence whic...
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

Bacterial flora, gas and antibiotics
Publication date: July 2009 Source:Digestive and Liver Disease Supplements, Volume 3, Issue 2 Author(s): A. Colecchia , D. Festi , E. Scaioli , V. Ruggiero , M. Berardino , P. Portincasa The human gastrointestinal microflora is a complex ecosystem with about 500 different bacterial species. In healthy individuals, the human stomach and the proximal small bowel contain only a few bacterial species, with the terminal ileum considered a transitional zone between the proximal small bowel aerobic microflora and the colonic anaerobic bacteria. The colon hosts a complex and variegate microbiota, including anaerobes (bacteroides...
Source: Digestive and Liver Disease Supplements - May 17, 2015 Category: Gastroenterology Source Type: research

Treatment options for small intestinal bacterial overgrowth
Publication date: July 2009 Source:Digestive and Liver Disease Supplements, Volume 3, Issue 2 Author(s): M. Gabrielli , L. Sparano , D. Roccarina , G. Vitale , E.C. Lauritano , A. Gasbarrini The best therapeutic approach for patients with small bowel bacterial overgrowth is a combination of the removal of all predisposing conditions and the administration of broad-spectrum antibiotics. In the case of non-modifiable predisposing factors, patients with bacterial overgrowth need a strict follow-up after successful decontamination with antibiotics, in order to promptly assess and treat disease recurrence. Up to now, the choi...
Source: Digestive and Liver Disease Supplements - November 2, 2014 Category: Gastroenterology Source Type: research

Small intestinal bacterial overgrowth
Publication date: July 2009 Source:Digestive and Liver Disease Supplements, Volume 3, Issue 2 Author(s): A. Parodi , E.C. Lauritano , G. Nardone , L. Fontana , V. Savarino , A. Gasbarrini In the adult, the human intestine houses myriads of microorganisms, quantitatively up to 100 trillion and qualitatively over 500 species of bacteria, exceeding the number of host somatic cells by at least one order of magnitude. Actually, it remains a mystery as to how the intestine is able to contain such large quantities of bacteria without evident harm to the host. However, it is well known that a very complex symbiotic relationship ...
Source: Digestive and Liver Disease Supplements - November 2, 2014 Category: Gastroenterology Source Type: research

Role of hydrogen and methane breath testing in gastrointestinal diseases
Publication date: July 2009 Source:Digestive and Liver Disease Supplements, Volume 3, Issue 2 Author(s): M. Di Stefano , G.R. Corazza The hydrogen and methane breath test represents a very simple, cheap, non-invasive diagnostic procedure to evaluate intraluminal events occurring in the gastrointestinal tract. Its clinical applications are, first of all, lactose malabsorption and small bowel bacterial overgrowth, but it has also been used to evaluate mouth-to-cecum transit time, sweetener malabsorption and intestinal mucosa integrity. Methodological aspects should be better evaluated and an improvement of its accuracy sho...
Source: Digestive and Liver Disease Supplements - November 2, 2014 Category: Gastroenterology Source Type: research